Environmental, Social And Governance Report

Overview

The report describes RemeGen's 2021 marketing approvals for Telitacicept and Disitamab Vedotin. It reports 2,082 employees under labour contracts and comprehensive energy utilization of 7,344.83 tce. Environmental disclosures include 22,183.04 tonne(s) of CO2e in Scope 2 and separate hazardous and non-hazardous waste totals.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services